Post-marketing requirement study to evaluate the safety of Octaplas™ versus plasma in patients undergoing orthotopic liver transplantation with special emphasis on hyperfibrinolysis,
Role: Investigator,
Octapharma,
(06/2018 - 06/2019)
Status: Completed
A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015),
Role: Investigator,
Novartis Pharmaceuticals Corporation,
(02/2018 - 02/2019)
Status: Completed
A prospective observational trial to evaluate the correlation of T-SPOT® response to CMV infection and T cell-mediated acute graft rejection. The PROTECT Study (PROTECT, May 2015),
Role: Investigator,
Oxford Immunotec,
(07/2017 - 07/2018)
Status: Completed
Internal
The role of B cells in kidney allograft dysfunction (B cell 3/1/2014),
Role: Investigator,
LLU Transplantation Institute,
(06/2022 - 06/2023)
Status: Completed
Clinical outcomes of induction therapies in renal transplant patients,
Role: Investigator,
LLU Transplantation Institute,
(12/2007 - 12/2015)
Status: Completed
Non-Profit Organization
Characterization of Immune-editing Mechanisms in the Microenvironment of Hepatocellular Carcinoma,
Role: Principal Investigator,
Association for the Study of Liver Diseases,
(05/2015 - 12/2016)
Status: Closed
Inhibition of Circulating Osteopontin Inhibits Growth and Metastasis of Hepatocellular Cancer,
Role: Principal Investigator,
American College of Surgeons,
(01/2015 - 03/2016)
Status: Closed
Characterization of Immune-editing Mechanisms in the Microenvironment of Hepatocellular Carcinoma,
Role: Principal Investigator,
Central Surgical Association,
(01/2015 - 12/2019)
Status: Closed